Takeaways: Knight Therapeutics’ Canadian launch of WYNZORA strengthens its dermatology portfolio and marks the commercialization of a product it inherited through the Paladin acquisition. The launch a...
Takeaways: Health Canada’s approval of ZORYVE cream 0.05% extends Arcutis’ topical atopic dermatitis franchise into the preschool population, addressing a treatment gap in a disease that frequently be...
Takeaways: Silo Pharma’s CIPO Notice of Allowance for SPC‑15 strengthens its IP moat around a prophylactic, intranasal 5‑HT4 agonist approach for PTSD and stress‑induced disorders, complementing a rec...
Takeaways: Roche Canada’s completion of pCPA negotiations for Perjeta (pertuzumab) in the neoadjuvant setting (with trastuzumab + chemotherapy) for HER2‑positive, locally advanced, inflammatory...
Takeaways: CDA‑AMC’s positive, conditional reimbursement recommendation for Nucala (mepolizumab) in adults with COPD and raised blood eosinophils who remain uncontrolled on ICS/LABA/LAMA triple therap...
Takeaways: The expanded approval of Lynkuet for AET‑related VMS gives Canadian oncologists and breast cancer patients the first non‑hormonal, evidence‑based option specifically indicated for...
Takeaways: Light AI’s Health Canada Class II license for QuickScan Strep A clears the way to commercialize an AI‑based clinical decision support tool that analyzes digital throat images to h...
Takeaways: By placing TRUFORMA analyzers in equine clinics at no cost and offering free PPID testing cartridges to eligible Boehringer Ingelheim customers, the program makes it much easier and faster ...
Takeaways: Slenyto gives Canadian clinicians a prescription, extended‑release melatonin specifically studied for children and teens (ages 2 to <18) with autism spectrum disorder and/or Smith‑Mageni...
Takeaways: DeltaSleep’s Notte Series gives Canadian clinics and patients a locally made, Health Canada–licensed CPAP/APAP/BiPAP option that runs very quietly (≤26 dB) and sends therapy data to a Canad...
